Anthem Bioscienc Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹594 Cr +8% YoYSee revenue, profit and what management said. You are viewing Q2 FY26.
AB

Anthem Bioscienc

Q2 FY26Pharmaceuticals & Biotechnology

Anthem Bioscienc Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹550Cr
+4.8% YoY
+1.9% QoQ
Net profit
₹173Cr
+6.8% YoY
+27.2% QoQ
Margin
40%
+3 pp YoY
+5 pp QoQ
Price₹871
Market cap₹50.1K Cr
P/E84.5

The short version

Anthem Biosciences targets a compound annual growth rate (CAGR) of around 20% in revenue over the next several years, consistent with its past 10-15 years' performance. Anthem Biosciences targets a revenue CAGR of approximately 20% over the next 5-10 years, consistent with its historical growth.

From Anthem Bioscienc's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Anthem Biosciences targets a compound annual growth rate (CAGR) of around 20% in revenue over the next several years, consistent with its past 10-15 years' performance.
  • Recent approval of 4 new commercial molecules is expected to drive growth, though some may be in pre-launch phases affecting immediate supply volumes.
  • Quarterly revenues may be lumpy due to fluctuating customer demand, but an overall upward trend is expected annually.
  • Existing molecules are growing robustly, with customers managing inventories carefully, which may temporarily affect volumes but growth remains strong.
  • Expansion projects (Unit-III and Unit-IV) and new capacities (e.g., 130 kiloliters added recently, Unit-IV with 400 kiloliters planned) aim to support increased volumes and revenues.

2 more points from Anthem Bioscienc's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Anthem Bioscienc said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Unit-IV: Rs. 1,000 Cr CAPEX planned for greenfield expansion with ~400 KL custom synthesis and ~100-200 KL fermentation capacity, expected to be commissioned within 2 years (by FY27-FY28).
  • Unit-III: Additional Rs. 100 Cr CAPEX to complete fermentation facilities by end of current year; limited further CAPEX expected afterward.
  • Unit-II: CP 6 and CP 7 expansions (~130 KL capacity) recently commissioned with Rs. 350 Cr plus Rs. 100 Cr CAPEX done; generating revenue potential of ~Rs. 300 Cr.
  • Focus on filling existing expanded capacities (Units II & III) before ramping up Unit-IV.

2 more points from Anthem Bioscienc's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Anthem Bioscienc said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Anthem Biosciences has observed a healthy inflow of new inquiries and RFPs, indicating a strong order book pipeline.
  • The company mentions being ready with capacities (including Unit-III and upcoming Unit-IV) to service new RFPs over the next 2-3 years.
  • The commissioning of Unit-III has already started generating revenues (~Rs. 55 Cr WIP), with plans to ramp this up to Rs. 100-150 Cr, supporting order execution.

2 more points from Anthem Bioscienc's call on order book

Create a free account to keep reading this call

Anthem Bioscienc — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Anthem Bioscienc Q2 FY26 results — key figures

Anthem Bioscienc Q2 FY26 reported results vs Q2 FY25, ₹ crore
₹ CrQ2 FY26Q2 FY25YoYQ1 FY26QoQ
Revenue550525+4.8%540+1.9%
Operating profit (EBITDA)218195+11.8%191+14.1%
Operating margin40%37%+3 pp35%+5 pp
Profit before tax230200+15%186+23.7%
Net profit (PAT)173162+6.8%136+27.2%
EPS (₹)3.092.90+6.6%2.42+27.7%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹594 Cr, net profit ₹211 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Bajaj Healthcare (Q2 FY26)

    For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

  • Infinium Pharma (Q2 FY26)

    Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium

  • Wanbury (Q2 FY26)

    Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q2 FY26)

    Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Anthem Bioscienc and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Anthem Bioscienc Q2 FY26 results?

Anthem Biosciences targets a compound annual growth rate (CAGR) of around 20% in revenue over the next several years, consistent with its past 10-15 years' performance. Anthem Biosciences targets a revenue CAGR of approximately 20% over the next 5-10 years, consistent with its historical growth.

What is Anthem Bioscienc share price analysis?

Anthem Bioscienc currently shows a neutral. The stock trades at a P/E of 84.5 with a market cap of ₹50,132 Cr. Investors should review the full earnings analysis for detailed insights.

Is Anthem Bioscienc planning capital expenditure?

Unit-IV: Rs. 1,000 Cr CAPEX planned for greenfield expansion with ~400 KL custom synthesis and ~100-200 KL fermentation capacity, expected to be commissioned within 2 years (by FY27-FY28).

Keep Anthem Bioscienc on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.